Injection Bupernorphine with intrathecal injection Ropivacaine for intensity of pain relief in Cesarean section patients
Phase 3
- Conditions
- Health Condition 1: 1- Obstetrics
- Registration Number
- CTRI/2024/04/065962
- Lead Sponsor
- Department of Anesthesiology and Critical Care
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients undergoing Elective Caesarean section
ASA I/II
Height between 145-160 cm
Pregnant pregnancy weight between 45- 80 kg
Exclusion Criteria
Patients with coagulopathy; Patients with severe PIH, Pre-Eclampsia or Eclampsia; Patients with hepatic, cardiac, renal or neurological disease.
Patients not willing for spinal anaesthesia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study effect of intrathecal hyperbaric Ropivacaine 0.75% 2ml compared to intrathecal hyperbaric Ropivacaine 0.75% with two different dosage of Bupernorphine 30ug & 60ug for characteristics of sensory and motor blockade. And also the postoperative analgesia duration and analgesic requirements.Timepoint: 4 mths
- Secondary Outcome Measures
Name Time Method Hemodynamic parameters <br/ ><br>Complications <br/ ><br>APGAR scoreTimepoint: 3-4 months